Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Free Cash Flow (2023 - 2025)

NewAmsterdam Pharma's Free Cash Flow history spans 3 years, with the latest figure at -$41.0 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 9.31% year-over-year to -$41.0 million; the TTM value through Dec 2025 reached -$148.0 million, up 7.04%, while the annual FY2025 figure was -$148.0 million, 7.04% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$41.0 million at NewAmsterdam Pharma, down from -$32.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$12.6 million in Q3 2024 and bottomed at -$55.0 million in Q1 2024.
  • The 3-year median for Free Cash Flow is -$37.0 million (2024), against an average of -$37.4 million.
  • The largest annual shift saw Free Cash Flow surged 73.23% in 2024 before it plummeted 160.88% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at -$33.1 million in 2023, then fell by 13.32% to -$37.5 million in 2024, then dropped by 9.31% to -$41.0 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Free Cash Flow are -$41.0 million (Q4 2025), -$32.8 million (Q3 2025), and -$37.8 million (Q2 2025).